Skip to main content
Premium Trial:

Request an Annual Quote

Arizona Entrepreneur Pledges $3M to TGen for Breast Cancer Research

NEW YORK, April 6 (GenomeWeb News) - The Translational Genomics Research Institute said on Monday that an Arizona entrepreneur had pledged $3 million to support three breast cancer research projects.

 

The projects include a study to enable physicians to diagnose and treat patients who have a genetic predisposition for developing breast cancer; a study to determine which tumors are most likely to respond to a particular therapy; and a prospective study based on the previous two studies to determine the most effective treatments for individual tumors based on their genetic information.

 

The entrepreneur, Ray Thurston, who founded a courier company that was acquired by United Parcel Service in 1995, also plans to assist TGen in "streamlining processes that expedite research and ultimately reduce the time required for the development of new diagnostic tests and drug treatments," according to the institute.

 

TGen researchers have already begun training Thurston in "molecular biology, including mandatory lessons in laboratory safety," TGen said.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.